Agitation in Alzheimer's Disease, Alzheimer's disease
NMRANeumora TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for NMRA-511 in Agitation in Alzheimer's Disease, Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
6/20/24- Initiated Ph1b trial. 5/12/25- Enrollment ongoing. 8/6/25- Report data by YE 2025. 11/6/25:- On track to report Phase 1b AD agitation data around end of 2025. 01/05/26:- Ph1b AD agitation study showed positive efficacy and safety; MAD extension study and ER formulation planned in 2026. 03/30/26:- New Ph1b analysis shows agitation benefit; higher-dose multiple ascending cohort data H2 2026; Ph2 Alzheimer's agitation initiation Q1 2027. 05/07/26:- Ph1b study showed strong agitation reduction without somnolence; higher-dose MAD expansion cohort data expected in H2 2026. 06/15/26:- Higher-dose MAD cohort completion expected Q4 2026; Phase 2b initiation planned by end 2026. 08/14/26:- Higher-dose MAD expansion cohort data will be reported in Q4 2026; Phase 2 initiation will occur by end of 2026.
Verification
Confirm timing and program details against the company announcement or filing.